Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$412M |
| 2 |
Advanced Micro Devices
AMD
|
+$294M |
| 3 |
Apple
AAPL
|
+$244M |
| 4 |
Qualcomm
QCOM
|
+$207M |
| 5 |
Pinduoduo
PDD
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$510M |
| 2 |
Uber
UBER
|
+$419M |
| 3 |
Chevron
CVX
|
+$286M |
| 4 |
Meta Platforms (Facebook)
META
|
+$255M |
| 5 |
NVO
Novo Nordisk
NVO
|
+$215M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.64% |
| 2 | Healthcare | 18.28% |
| 3 | Consumer Discretionary | 13.73% |
| 4 | Industrials | 8.65% |
| 5 | Financials | 7.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CARM
3026
DELISTED
Carisma Therapeutics
CARM
| $212K | ﹤0.01% |
139,360
-86,635
| -38% | -$129K |
|
3027
Lipocine
LPCN
$17M
| $212K | ﹤0.01% |
25,697
+4,600
| +22% | +$28.8K |
|
|
IOBT
3028
DELISTED
IO Biotech
IOBT
| $212K | ﹤0.01% |
180,800
+13,600
| +8% | +$19K |
|
3029
Marker Therapeutics
MRKR
$18.5M
| $211K | ﹤0.01% |
38,850
+1,600
| +4% | +$6.8K |
|
3030
HF Foods Group
HFFG
$97.6M
| $211K | ﹤0.01% |
70,300
+5,000
| +8% | +$15.9K |
|
|
RGLS
3031
DELISTED
Regulus Therapeutics
RGLS
| $211K | ﹤0.01% |
118,100
+42,600
| +56% | +$98.9K |
|
3032
First Trust Capital Strength ETF
FTCS
$8.02B
| $210K | ﹤0.01% |
2,500
-22,000
| -90% | -$1.84M |
|
3033
Mesa Laboratories
MLAB
$631M
| $208K | ﹤0.01% |
2,400
-13,700
| -85% | -$1.43M |
|
|
HSAI
3034
Hesai Group
HSAI
$3.03B
| $208K | ﹤0.01% |
49,700
+15,200
| +44% | +$72.3K |
|
3035
Equillium
EQ
$138M
| $208K | ﹤0.01% |
300,400
+91,200
| +44% | +$130K |
|
3036
Bolt Biotherapeutics
BOLT
$6.63M
| $208K | ﹤0.01% |
13,837
-12,045
| -47% | -$238K |
|
3037
German American Bancorp
GABC
$1.92B
| $207K | ﹤0.01% |
+5,849
| New | +$191K |
|
3038
PEDEVCO
PED
$160M
| $206K | ﹤0.01% |
11,391
+466
| +4% | +$8.5K |
|
3039
CareCloud
CCLD
$104M
| $206K | ﹤0.01% |
107,200
+21,500
| +25% | +$40.4K |
|
|
DAO
3040
Youdao
DAO
$2.23B
| $205K | ﹤0.01% |
52,300
+3,300
| +7% | +$12.4K |
|
3041
First Trust RBA American Industrial Renaissance ETF
AIRR
$10.7B
| $205K | ﹤0.01% |
+3,000
| New | +$204K |
|
|
ATXS
3042
DELISTED
Astria Therapeutics
ATXS
| $204K | ﹤0.01% |
22,461
-18,939
| -46% | -$185K |
|
|
CTHR
3043
DELISTED
Charles & Colvard Ltd
CTHR
| $204K | ﹤0.01% |
119,069
-19,568
| -14% | -$52.7K |
|
3044
ClearOne Inc
CLRO
$15.2M
| $204K | ﹤0.01% |
20,877
-1,327
| -6% | -$18.6K |
|
|
SSY
3045
DELISTED
SunLink Health Systems
SSY
| $203K | ﹤0.01% |
253,478
-2,900
| -1% | -$1.97K |
|
3046
Priority Technology Holdings
PRTH
$458M
| $202K | ﹤0.01% |
+38,300
| New | +$145K |
|
3047
CEL-SCI Corp
CVM
$26M
| $202K | ﹤0.01% |
5,793
+1,333
| +30% | +$56.8K |
|
3048
Direxion Daily Energy Bear 2X ETF
ERY
$36.4M
| $202K | ﹤0.01% |
+8,800
| New | +$198K |
|
3049
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
$19.1B
| $200K | ﹤0.01% |
3,900
-1,200
| -24% | -$61.9K |
|
3050
Globalstar
GSAT
$10.8B
| $198K | ﹤0.01% |
11,775
+1,346
| +13% | +$24.3K |
|
Similar funds
Jim Simons's Q2 2024 Portfolio in Review
As of Q2 2024, Jim Simons held 4,123 positions worth $59B, down 7.3% from $63.6B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $4.49B in Q2 2024, closing 674 positions and reducing 1,503 holdings. Its most notable exit was Bank of America, an estimated $142M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Broadcom worth $472M.
- Jim Simons's largest Q2 2024 buy was Broadcom: 2,941,150 shares worth $472M.
- Jim Simons added most to Apple in Q2 2024, an estimated $244M increase.
- Jim Simons's biggest Q2 2024 reduction was Amazon, cutting an estimated $510M.
- Jim Simons fully exited Bank of America in Q2 2024, selling an estimated $142M.
- Jim Simons's ten largest holdings make up 12% of its $59B portfolio in Q2 2024.
- Jim Simons opened 463 new positions and closed 674 in Q2 2024.
- Jim Simons's portfolio value fell 7.3% quarter-over-quarter to $59B.
Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.